Research and Development

A recent study, conducted by the University of Cambridge, has found that DNA plays a part in determining an individual’s …

Novartis is to join forces with tech giant IBM and its Watson Health platform to tackle advanced breast cancer with …

Researchers celebrated a world-first at the American Society of Clinical Oncology conference, revealing data which showed that, in a study …

Takeda has officially launched the construction of a new €40 million expansion of its production facility in Dublin, Ireland, with …

New research data from the Mayo Clinic has suggested that as much as one in six patients suffering from atrial …

Servier, a French pharmaceutical firm, has sought to lower the fine it received from the European Commission for breaching antitrust …

The University of Oxford has joined forces with the Netherlands Cancer Institute (NKI) in an international collaboration known as Scenic …

Novartis and Bristol-Myers Squibb have announced they are to enter a clinical research partnership to investigate and assess the effectiveness …

A new tool developed by the Association of the British Pharmaceutical Industry could lead to stronger research relationships between the …

New data from late-stage trials suggests that Pfizer’s dacomitinib beat out AstraZeneca’s rival treatment Iressa (gefitinib) at halting the progression …

To view the original whitepaper from NDA, please click here.Small and Medium Sized Companies in North America Lead Novel Drug …

Recipharm, the contract development and manufacturing organisation (CDMO), has opened a newly built GMP suite for clinical trial material (CTM) …

Yannis Natsis, Policy Manager for Universal Access and Affordable Medicines at the European Public Health Alliance (EPHA), discusses the latest …

Bristol-Myers Squibb has announced that its flagship immunotherapy treatment Opdivo (nivolumab) has secured its eighth approval in Europe as the …

Research funded by Cancer Research UK has found that abiraterone added to hormone therapy improved survival by over a third …